Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desidustat vs Epoetin Alfa for Anemia in CKD on Dialysis
NCT04215120Phase 3Completed
- Sponsor
- Zydus Lifesciences Limited
- Start
- Jan 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of desidustat in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by Zydus Lifesciences Limited. Primary endpoint: Change in Hemoglobin level from baseline at 24 weeks. Started Jan 2020; status: completed.
02
Drugs
desidustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT04215120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04215120.